Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
Completed
UNC Lineberger Comprehensive Cancer Center
Phase 2
1998-12-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells
and either kill them or deliver tumor-killing substances to them without harming normal
cells. Combining chemotherapy, monoclonal antibody therapy, and surgery may be a more
effective treatment for breast cancer.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, monoclonal
antibody therapy, and surgery in treating women who have stage II, stage III, or stage IV
breast cancer.
This research study is studying a combination of chemotherapy drugs as a possible treatment
for aggressive lymphoma that has not responded to standard treatment.
The names of the study interventions involved in this study are:
- Cyclophosphamide
- Alemtuzumab
This research study is studying a combination of chemotherapy drugs as a possible treatment
for aggressive lymphoma that has not responded to standard treatment.
The names of the study interventions involved in this study are:
- Cyclophosphamide
- Alemtuzumab
This research study is studying a combination of chemotherapy drugs as a possible treatment
for aggressive lymphoma that has not responded to standard treatment.
The names of the study interventions involved in this study are:
- Cyclophosphamide
- Alemtuzumab
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
